Cellectis CLLS
NASDAQ CLLS
$3.24 -0.08 (-2.41%)
At close: Sep 4, 2026 · 4:00 PM EDT

Cellectis (CLLS) Goodwill & Intangibles (2013 - 2026)

Cellectis (CLLS) posted quarterly Goodwill & Intangibles of -$33.0 million for Q1 2026, up 10.95% year-over-year from -$29.7 million in Q1 2025, and down 0.59% quarter-over-quarter from -$32.8 million in Q4 2025.

Analysis

Cellectis (CLLS) Goodwill & Intangibles (2013 - 2026) Analysis & Trends

Cellectis' Goodwill & Intangibles history runs 14 years deep, the most recent figure standing at -$33.0 million for Q1 2026.

  • In Q1 2026, Goodwill & Intangibles rose 10.95% year-over-year to -$33.0 million; the TTM figure through Mar 2026 stood at -$33.0 million (up 10.95% YoY), while the FY2025 annual figure was -$32.8 million, up 14.68% from the prior year.
  • Goodwill & Intangibles for Q1 2026 stood at -$33.0 million, down from -$32.8 million in the prior quarter.
  • The five-year high for Goodwill & Intangibles was -$19.6 million in Q1 2022, with the low at -$38.4 million in Q4 2024.
  • The 5-year median for Goodwill & Intangibles is -$33.9 million (2022), against an average of -$33.0 million.
  • The sharpest annual moves came in 2022 and 2025: Goodwill & Intangibles slumped 249.74% in 2022, then rose 14.68% in 2025.
  • Cellectis' Goodwill & Intangibles stood at -$27.9 million in 2022, then fell by 29.16% to -$36.0 million in 2023, then retreated by 6.67% to -$38.4 million in 2024, then rose by 14.68% to -$32.8 million in 2025, then decreased by 0.59% to -$33.0 million in 2026.
  • Business Quant data shows CLLS's Goodwill & Intangibles at -$33.0 million in Q1 2026, -$32.8 million in Q4 2025, and -$31.9 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Cellectis 321.90 Mn 155.05 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.12 Mn
Mar 31, 2026 221,000.00
Dec 31, 2025 535,000.00
Sep 30, 2025 845,000.00
Jun 30, 2025 1.15 Mn
Mar 31, 2025 242,000.00
Dec 31, 2024 1.12 Mn
Sep 30, 2024 691,000.00
Jun 30, 2024 653,000.00
Mar 31, 2024 677,000.00
Dec 31, 2023 671,000.00
Sep 30, 2023 662,000.00
Jun 30, 2023 695,000.00
Mar 31, 2023 713,000.00
Dec 31, 2022 718,000.00
Sep 30, 2022 1.51 Mn
Jun 30, 2022 1.58 Mn
Mar 31, 2022 1.70 Mn
Dec 31, 2021 1.85 Mn
Sep 30, 2021 2.55 Mn